Bell Potter fined in 2017 for price manipulation, page-3

I actually think it's higher, but as everything happens at the margin and we are cashflow negative, nothing will change until we turn that around.

I have learned through owning medtech and biotech shares is that doctors are very conservative and will only change their protocols when forced or when the weight of evidence is overwhelming. It means that this share will take a long time to reach its ultimate potential/fair value.

So with little cash left and negative cashflow, there's more dilution coming.

There is also no interest from insiders!